Cullinan Oncology Inc
NASDAQ:CGEM
Cullinan Oncology Inc
Accrued Liabilities
Cullinan Oncology Inc
Accrued Liabilities Peer Comparison
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cullinan Oncology Inc
NASDAQ:CGEM
|
Accrued Liabilities
$25.6m
|
CAGR 3-Years
77%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$5.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
28%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Cullinan Oncology Inc's Accrued Liabilities?
Accrued Liabilities
25.6m
USD
Based on the financial report for Dec 31, 2023, Cullinan Oncology Inc's Accrued Liabilities amounts to 25.6m USD.
What is Cullinan Oncology Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
91%
Over the last year, the Accrued Liabilities growth was 67%. The average annual Accrued Liabilities growth rates for Cullinan Oncology Inc have been 77% over the past three years , 91% over the past five years .